This document discusses biocompatibility, which refers to the properties of materials being biologically compatible within a living system without eliciting toxic responses. From a regulatory perspective, biocompatibility involves tests to determine potential toxicity from medical device components contacting the body. Common biomaterials used include silicone rubber, Dacron, cellulose, poly(methyl methacrylate), polyurethanes, stainless steel, titanium, alumina, and hydroxyapatite. Both in vivo and in vitro testing methods are described to evaluate factors like cytotoxicity, hemocompatibility, sensitization, and irritation. Manufacturers are responsible for demonstrating the safety and efficacy of their finished, sterilized devices through appropriate biocompatibility studies.
Biocompatibility - ability of material to elicit an appropriate biological response on a given application in the body.
The ability of a material to perform with an appropriate host response in a specific application", Williams' definition.
"The quality of not having toxic or injurious effects on biological systems".
ISO 10993 Series Part 1: Evaluation and Testing In The Risk Management ProcessNAMSA
ISO 10993 Series Part 1: Evaluation and Testing In The Risk Management Process discusses what ISO 10993-1 addresses, as well as the general principles governing the biological evaluation of medical devices within a risk management process.
Toxicological Risk Assessment For Medical Devices - ISO 10993-1Russell Sloboda
Russell Sloboda presented on toxicological risk assessment for medical devices. He discussed how risk assessment plays an increasing role in preclinical safety evaluation under ISO 10993-1. Key points included how chemical characterization data forms the basis for risk assessment, and how tools like threshold of toxicological concern, quantitative structure-activity relationship analysis, and permissible exposure thresholds can be applied to evaluate risks. The goal of risk assessment is to identify hazards, evaluate exposure levels, and characterize overall risks to determine if biological testing is needed.
This document discusses the history and development of biomaterials. It begins by describing early biomaterials like gold, iron, brass and glass that were used by physicians with little consideration of material properties. The document then outlines major developments in biomaterials from the 1860s to the present day for applications like orthopedics, dental, cardiovascular and others. Key points covered include the regulatory framework for biomaterials and medical devices as well as current and future directions in the field.
Biomaterials and their interactions with biological systems were discussed. Historically, biomaterials consisted of common laboratory materials with little consideration of properties. Modern definitions characterize biomaterials as materials intended to interact with biological systems. An ideal biomaterial is inert, biocompatible, mechanically stable, and elicits an appropriate host response for a specific application. Surface properties and bulk properties were described as important for biomaterial performance and biocompatibility. Characterization techniques for analyzing biomaterial properties were also outlined.
This document discusses biocompatibility, which refers to the properties of materials being biologically compatible within a living system without eliciting toxic responses. From a regulatory perspective, biocompatibility involves tests to determine potential toxicity from medical device components contacting the body. Common biomaterials used include silicone rubber, Dacron, cellulose, poly(methyl methacrylate), polyurethanes, stainless steel, titanium, alumina, and hydroxyapatite. Both in vivo and in vitro testing methods are described to evaluate factors like cytotoxicity, hemocompatibility, sensitization, and irritation. Manufacturers are responsible for demonstrating the safety and efficacy of their finished, sterilized devices through appropriate biocompatibility studies.
Biocompatibility - ability of material to elicit an appropriate biological response on a given application in the body.
The ability of a material to perform with an appropriate host response in a specific application", Williams' definition.
"The quality of not having toxic or injurious effects on biological systems".
ISO 10993 Series Part 1: Evaluation and Testing In The Risk Management ProcessNAMSA
ISO 10993 Series Part 1: Evaluation and Testing In The Risk Management Process discusses what ISO 10993-1 addresses, as well as the general principles governing the biological evaluation of medical devices within a risk management process.
Toxicological Risk Assessment For Medical Devices - ISO 10993-1Russell Sloboda
Russell Sloboda presented on toxicological risk assessment for medical devices. He discussed how risk assessment plays an increasing role in preclinical safety evaluation under ISO 10993-1. Key points included how chemical characterization data forms the basis for risk assessment, and how tools like threshold of toxicological concern, quantitative structure-activity relationship analysis, and permissible exposure thresholds can be applied to evaluate risks. The goal of risk assessment is to identify hazards, evaluate exposure levels, and characterize overall risks to determine if biological testing is needed.
This document discusses the history and development of biomaterials. It begins by describing early biomaterials like gold, iron, brass and glass that were used by physicians with little consideration of material properties. The document then outlines major developments in biomaterials from the 1860s to the present day for applications like orthopedics, dental, cardiovascular and others. Key points covered include the regulatory framework for biomaterials and medical devices as well as current and future directions in the field.
Biomaterials and their interactions with biological systems were discussed. Historically, biomaterials consisted of common laboratory materials with little consideration of properties. Modern definitions characterize biomaterials as materials intended to interact with biological systems. An ideal biomaterial is inert, biocompatible, mechanically stable, and elicits an appropriate host response for a specific application. Surface properties and bulk properties were described as important for biomaterial performance and biocompatibility. Characterization techniques for analyzing biomaterial properties were also outlined.
This document provides an overview of metallic and nonmetallic implants used in orthopaedics. It discusses the history of implant materials dating back to ancient times and key developments. Common biomaterials used in orthopaedic implants include metals, ceramics, polymers, and composites. Popular metal implant materials include stainless steel, cobalt-chromium alloys, and titanium alloys. The document also covers basic biomechanics principles and compares the mechanical properties of bone and common implant materials.
Chemical Characterization of Plastic Used in Medical ProductsSGS
Dr. Andreas Nixdorf presented on chemical characterization of plastics used in medical products according to ISO 10993 standards. He discussed the normative framework for chemical characterization and analytical methods for identifying extractables and leachables. Key points included sample preparation according to ISO 10993-12, using both exaggerated and accelerated extraction conditions. A variety of analytical techniques were outlined for separation and detection of extractable substances.
PLGA is a biodegradable synthetic polymer commonly used for tissue engineering scaffolds. It consists of lactic acid and glycolic acid monomers linked together. PLGA degrades through hydrolysis of its ester linkages into lactic acid and glycolic acid, which can be metabolized by the body. It has properties suitable for bone tissue engineering like biocompatibility and ability to be tuned to degrade at different rates depending on monomer ratios. PLGA has applications as sutures, fixation devices, and drug delivery systems due to its biodegradability and tunable properties. Future areas of research include modifying PLGA scaffold surfaces and adding hydroxyapatite to improve osteoconductivity and mechanical properties for load-
Symbols Commonly Used in Medical Device Packaging and Labelingncor
This document lists various common symbols used in medical device packaging and labeling. It provides symbols for serial number, batch code, manufacturer, date of manufacture, caution, use by date, sterilization methods, non-sterile, single use, consult instructions, authorized representative, temperature limits, conformity assessment, non-ionizing radiation, shock protection type, general waste, sunlight, dry conditions, fragility, and recycling. The symbols are intended to clearly convey important information about medical devices on labels and packaging in accordance with international standards.
Material characterization per ISO 10993-18: When is it needed & how do I sati...UBMCanon
ISO 10993 provides guidance on biological evaluation of medical devices and consists of various parts covering topics like cytotoxicity, irritation, and systemic toxicity testing. Material characterization as outlined in Part 18 involves identifying all components that can migrate or leach out of a medical device under various conditions through extractable and leachable testing. Extractables are compounds that can migrate under aggressive extraction whereas leachables are those that migrate under normal exposure conditions. Understanding potential leachable sources from materials like polymers, metals, and residues is important for ensuring a comprehensive extractable/leachable profile.
This document discusses biomaterials and their applications. It defines biomaterials as materials that are compatible with living tissues or interact with biological systems. Some key points made include:
- Biomaterials have characteristics of being biocompatible, bioinert or biofunctional.
- Common biomaterials are used in applications like dental implants, hip replacements, and intraocular lenses.
- The properties of biomaterials that are important for their use in the body include mechanical, thermal, electrical, optical and surface properties.
This document provides an introduction to biomedical materials. It defines biomaterials and distinguishes them from biological materials. Biomaterials must be biocompatible, have adequate mechanical performance for their application, be designed appropriately for their application area, and be reproducibly fabricated. The document then classifies common biomaterials such as metals, polymers, ceramics, and composites. It provides examples of biomedical applications for each material type, including implants, scaffolds, stents, and more. Students are assigned to write a short presentation about a selected biomedical device, its application, materials used, and how material properties relate to the application.
The document discusses biomaterials, bio-implants, and biomedical devices. It provides:
1) Definitions of biomaterials, bio-implants, and biomedical devices and how they interact with human tissue.
2) A brief history of the advancement of biomaterials and biomedical devices from ancient times to modern developments.
3) Classification of biomaterials into biological, synthetic, and composite categories and how they are evaluated.
This document provides an overview of biomaterials, including their definition, history, examples of applications, and challenges. Key points include:
- Biomaterials are nonviable materials used in medical devices and intended to interact with biological systems. Examples include implants, prosthetics, and tissue scaffolds.
- Biomaterials have evolved from common materials like metals and plastics to more advanced engineered materials. Current research aims to more closely mimic natural tissues.
- Successful biomaterials must be biocompatible, non-toxic, and able to integrate with the body over the long term without rejection or harmful reactions. Matching mechanical properties to tissues is also important.
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...NAMSA
ISO 10993-6 helps identify appropriate implantation sites, how long implants should remain in place during testing, implantation methods and biological responses at the macro- and microscopic level.
Polymers are large molecules formed by combining many small repeating units called monomers. There are several types of polymers classified by their source, structure, and method of formation. Polymers can be natural, synthetic, or semi-synthetic and can have linear, branched, or cross-linked structures. Polymerization is the process where monomers combine to form polymers and can occur through addition, condensation, or copolymerization reactions. Key properties of polymers like glass transition temperature and tacticity depend on factors like molecular weight and stereochemistry of the repeating units.
1) Biodegradable polymers are polymers that break down into non-toxic molecules via biological processes such as hydrolysis or enzymatic degradation. They are used for applications such as drug delivery where degradation is beneficial.
2) There are several types of biodegradable polymers including synthetic aliphatic polyesters like polylactic acid and polyglycolic acid, polyanhydrides, and natural polymers like collagen and gelatin. These polymers degrade via hydrolysis, surface erosion, or enzymatic degradation.
3) Biodegradable polymers have advantages for drug delivery such as localized and sustained release as well as reduced dosing requirements. However, challenges remain in controlling degradation rates and maintaining drug stability
The ICH Q3 guidelines address chemistry and safety aspects of impurities in pharmaceuticals. They define thresholds for reporting, identifying, and qualifying impurities in active pharmaceutical ingredients and finished drug products. Impurities include organic and inorganic compounds arising from manufacturing as well as residual solvents. The guidelines recommend identifying impurities above thresholds and qualifying those above identification levels through genotoxicity testing and evaluating risk to ensure product safety.
Our Quality Engineer, Madison Wheeler, discusses the characteristics of an efficient product development process for medical devices and how medical device product development should incorporate Quality, Regulatory, and Business needs in parallel.
Pending (Potential) Updates to ISO 10993-17.pdfRussell Sloboda
The document summarizes potential updates to ISO 10993-17, which provides guidance on conducting toxicological risk assessments of medical device constituents. Key changes in the proposed updates include introducing a Toxicological Screening Limit to streamline assessments, providing more detailed methodology for estimating exposure doses and applying threshold of toxicological concern values, and deriving tolerable intake limits for both cancer and non-cancer endpoints. The updates are intended to add clarity and conservatism to the risk assessment process. The revised draft is expected to undergo additional balloting with the goal of final approval and publication in 2022.
This document discusses biocompatible polymers. It begins by defining polymers as macromolecules formed from repeating structural units called monomers. Polymers can be classified based on their structure, mode of polymerization, molecular forces, degradability, and source. Biocompatible polymers are synthetic or natural polymers used in contact with living tissue or to replace parts of the body. They must be non-toxic, chemically inert, and able to withstand biological environments. Common applications of biocompatible polymers include tissue scaffolds, drug delivery systems, medical devices, and coatings to improve blood compatibility. Examples of specific biocompatible polymers and their applications are also provided.
This presentation provides basics of self healing polymers along with all the different types of polymers and mechanisms involved including a focus on new extrinsic and intrinsic technologies.It also discusses the applications of self healing polymers
The document discusses validation and calibration of equipment used in the pharmaceutical industry. It defines validation as establishing evidence that a process will consistently produce quality products. Calibration ensures instrument readings are accurate by comparing them to standards. The FDA provides guidelines for validation. Key equipment discussed include tablet presses, dissolution apparatus, friability equipment, balances, and stability chambers. Specifications and operating parameters are provided for each.
The document discusses the various applications of polymers in different areas. It describes how polymers are used in agriculture to improve soil aeration and plant growth through cross-linking polymers that can absorb large amounts of water. In medicine, polymers are used for cardiovascular applications as well as replacements for joints, fingers, and teeth. Polymers are also widely used in electronics as insulators in devices like TVs, computers, and transistors. Automobiles incorporate various polymers for parts like trim panels, impact absorbers, door panels, fog light covers, tires, and bumpers. Finally, polymers have applications in daily life for items like non-stick pans, cups, bottles, mattresses, furniture, toys, food packaging, ships, boats
The document outlines the key steps in the medical device design and development process as required by ISO 13485. This includes establishing procedures for design and development stages, planning with target dates and reviews, determining inputs, producing outputs like drawings and bills of materials, conducting reviews and verification to ensure outputs meet inputs, performing validation to ensure the product meets requirements, and controlling any changes to the design.
The document discusses the process manufacturers must go through to evaluate the biological safety of medical devices before marketing them. This includes systematically evaluating devices for bio-compatibility risks to avoid harming the human body. The ISO 10993 series provides international guidelines for biological evaluation and testing to confirm biocompatibility and mitigate risks to an acceptable level. Manufacturers must document their biological evaluation plan and testing program to support medical device assessment and ensure biological safety.
This document provides an overview of metallic and nonmetallic implants used in orthopaedics. It discusses the history of implant materials dating back to ancient times and key developments. Common biomaterials used in orthopaedic implants include metals, ceramics, polymers, and composites. Popular metal implant materials include stainless steel, cobalt-chromium alloys, and titanium alloys. The document also covers basic biomechanics principles and compares the mechanical properties of bone and common implant materials.
Chemical Characterization of Plastic Used in Medical ProductsSGS
Dr. Andreas Nixdorf presented on chemical characterization of plastics used in medical products according to ISO 10993 standards. He discussed the normative framework for chemical characterization and analytical methods for identifying extractables and leachables. Key points included sample preparation according to ISO 10993-12, using both exaggerated and accelerated extraction conditions. A variety of analytical techniques were outlined for separation and detection of extractable substances.
PLGA is a biodegradable synthetic polymer commonly used for tissue engineering scaffolds. It consists of lactic acid and glycolic acid monomers linked together. PLGA degrades through hydrolysis of its ester linkages into lactic acid and glycolic acid, which can be metabolized by the body. It has properties suitable for bone tissue engineering like biocompatibility and ability to be tuned to degrade at different rates depending on monomer ratios. PLGA has applications as sutures, fixation devices, and drug delivery systems due to its biodegradability and tunable properties. Future areas of research include modifying PLGA scaffold surfaces and adding hydroxyapatite to improve osteoconductivity and mechanical properties for load-
Symbols Commonly Used in Medical Device Packaging and Labelingncor
This document lists various common symbols used in medical device packaging and labeling. It provides symbols for serial number, batch code, manufacturer, date of manufacture, caution, use by date, sterilization methods, non-sterile, single use, consult instructions, authorized representative, temperature limits, conformity assessment, non-ionizing radiation, shock protection type, general waste, sunlight, dry conditions, fragility, and recycling. The symbols are intended to clearly convey important information about medical devices on labels and packaging in accordance with international standards.
Material characterization per ISO 10993-18: When is it needed & how do I sati...UBMCanon
ISO 10993 provides guidance on biological evaluation of medical devices and consists of various parts covering topics like cytotoxicity, irritation, and systemic toxicity testing. Material characterization as outlined in Part 18 involves identifying all components that can migrate or leach out of a medical device under various conditions through extractable and leachable testing. Extractables are compounds that can migrate under aggressive extraction whereas leachables are those that migrate under normal exposure conditions. Understanding potential leachable sources from materials like polymers, metals, and residues is important for ensuring a comprehensive extractable/leachable profile.
This document discusses biomaterials and their applications. It defines biomaterials as materials that are compatible with living tissues or interact with biological systems. Some key points made include:
- Biomaterials have characteristics of being biocompatible, bioinert or biofunctional.
- Common biomaterials are used in applications like dental implants, hip replacements, and intraocular lenses.
- The properties of biomaterials that are important for their use in the body include mechanical, thermal, electrical, optical and surface properties.
This document provides an introduction to biomedical materials. It defines biomaterials and distinguishes them from biological materials. Biomaterials must be biocompatible, have adequate mechanical performance for their application, be designed appropriately for their application area, and be reproducibly fabricated. The document then classifies common biomaterials such as metals, polymers, ceramics, and composites. It provides examples of biomedical applications for each material type, including implants, scaffolds, stents, and more. Students are assigned to write a short presentation about a selected biomedical device, its application, materials used, and how material properties relate to the application.
The document discusses biomaterials, bio-implants, and biomedical devices. It provides:
1) Definitions of biomaterials, bio-implants, and biomedical devices and how they interact with human tissue.
2) A brief history of the advancement of biomaterials and biomedical devices from ancient times to modern developments.
3) Classification of biomaterials into biological, synthetic, and composite categories and how they are evaluated.
This document provides an overview of biomaterials, including their definition, history, examples of applications, and challenges. Key points include:
- Biomaterials are nonviable materials used in medical devices and intended to interact with biological systems. Examples include implants, prosthetics, and tissue scaffolds.
- Biomaterials have evolved from common materials like metals and plastics to more advanced engineered materials. Current research aims to more closely mimic natural tissues.
- Successful biomaterials must be biocompatible, non-toxic, and able to integrate with the body over the long term without rejection or harmful reactions. Matching mechanical properties to tissues is also important.
ISO 10993-6: Biological Evaluation of Medical Devices - Tests for local effec...NAMSA
ISO 10993-6 helps identify appropriate implantation sites, how long implants should remain in place during testing, implantation methods and biological responses at the macro- and microscopic level.
Polymers are large molecules formed by combining many small repeating units called monomers. There are several types of polymers classified by their source, structure, and method of formation. Polymers can be natural, synthetic, or semi-synthetic and can have linear, branched, or cross-linked structures. Polymerization is the process where monomers combine to form polymers and can occur through addition, condensation, or copolymerization reactions. Key properties of polymers like glass transition temperature and tacticity depend on factors like molecular weight and stereochemistry of the repeating units.
1) Biodegradable polymers are polymers that break down into non-toxic molecules via biological processes such as hydrolysis or enzymatic degradation. They are used for applications such as drug delivery where degradation is beneficial.
2) There are several types of biodegradable polymers including synthetic aliphatic polyesters like polylactic acid and polyglycolic acid, polyanhydrides, and natural polymers like collagen and gelatin. These polymers degrade via hydrolysis, surface erosion, or enzymatic degradation.
3) Biodegradable polymers have advantages for drug delivery such as localized and sustained release as well as reduced dosing requirements. However, challenges remain in controlling degradation rates and maintaining drug stability
The ICH Q3 guidelines address chemistry and safety aspects of impurities in pharmaceuticals. They define thresholds for reporting, identifying, and qualifying impurities in active pharmaceutical ingredients and finished drug products. Impurities include organic and inorganic compounds arising from manufacturing as well as residual solvents. The guidelines recommend identifying impurities above thresholds and qualifying those above identification levels through genotoxicity testing and evaluating risk to ensure product safety.
Our Quality Engineer, Madison Wheeler, discusses the characteristics of an efficient product development process for medical devices and how medical device product development should incorporate Quality, Regulatory, and Business needs in parallel.
Pending (Potential) Updates to ISO 10993-17.pdfRussell Sloboda
The document summarizes potential updates to ISO 10993-17, which provides guidance on conducting toxicological risk assessments of medical device constituents. Key changes in the proposed updates include introducing a Toxicological Screening Limit to streamline assessments, providing more detailed methodology for estimating exposure doses and applying threshold of toxicological concern values, and deriving tolerable intake limits for both cancer and non-cancer endpoints. The updates are intended to add clarity and conservatism to the risk assessment process. The revised draft is expected to undergo additional balloting with the goal of final approval and publication in 2022.
This document discusses biocompatible polymers. It begins by defining polymers as macromolecules formed from repeating structural units called monomers. Polymers can be classified based on their structure, mode of polymerization, molecular forces, degradability, and source. Biocompatible polymers are synthetic or natural polymers used in contact with living tissue or to replace parts of the body. They must be non-toxic, chemically inert, and able to withstand biological environments. Common applications of biocompatible polymers include tissue scaffolds, drug delivery systems, medical devices, and coatings to improve blood compatibility. Examples of specific biocompatible polymers and their applications are also provided.
This presentation provides basics of self healing polymers along with all the different types of polymers and mechanisms involved including a focus on new extrinsic and intrinsic technologies.It also discusses the applications of self healing polymers
The document discusses validation and calibration of equipment used in the pharmaceutical industry. It defines validation as establishing evidence that a process will consistently produce quality products. Calibration ensures instrument readings are accurate by comparing them to standards. The FDA provides guidelines for validation. Key equipment discussed include tablet presses, dissolution apparatus, friability equipment, balances, and stability chambers. Specifications and operating parameters are provided for each.
The document discusses the various applications of polymers in different areas. It describes how polymers are used in agriculture to improve soil aeration and plant growth through cross-linking polymers that can absorb large amounts of water. In medicine, polymers are used for cardiovascular applications as well as replacements for joints, fingers, and teeth. Polymers are also widely used in electronics as insulators in devices like TVs, computers, and transistors. Automobiles incorporate various polymers for parts like trim panels, impact absorbers, door panels, fog light covers, tires, and bumpers. Finally, polymers have applications in daily life for items like non-stick pans, cups, bottles, mattresses, furniture, toys, food packaging, ships, boats
The document outlines the key steps in the medical device design and development process as required by ISO 13485. This includes establishing procedures for design and development stages, planning with target dates and reviews, determining inputs, producing outputs like drawings and bills of materials, conducting reviews and verification to ensure outputs meet inputs, performing validation to ensure the product meets requirements, and controlling any changes to the design.
The document discusses the process manufacturers must go through to evaluate the biological safety of medical devices before marketing them. This includes systematically evaluating devices for bio-compatibility risks to avoid harming the human body. The ISO 10993 series provides international guidelines for biological evaluation and testing to confirm biocompatibility and mitigate risks to an acceptable level. Manufacturers must document their biological evaluation plan and testing program to support medical device assessment and ensure biological safety.
Considerations for Biocompatibility EvaluationEMMAIntl
Biocompatibility is one of the most critical performance studies that manufacturers need to perform as part of their product development process. ISO 10993-5 and ISO 10993-10 are FDA-recognized standards for biocompatibility. Whether you perform these studies in-house or send out samples to a third-party lab the protocol for biocompatibility assessment must be conducted in accordance with ISO 10993...
Biosimilars are biopharmaceutical drugs that are similar to an existing approved biologic drug (the reference product). Biosimilars undergo a step-wise comparability exercise to demonstrate similarity in structure, function, safety and efficacy to the reference product. Regulatory agencies such as the FDA and EMA require extensive characterization, non-clinical and clinical studies to establish biosimilarity. Guidelines for approval of biosimilars have been established in regions such as Europe, US, Korea, Singapore and India to enable a pathway for approval of biosimilar versions of biologic drugs.
Bioburden refers to the number of microorganisms contaminating a material prior to sterilization. Bioburden testing measures the total microbial count on medical devices before final sterilization and use. It is important for quality control and ensuring sterilization processes are effective at eliminating microbes. Routine bioburden testing helps manufacturers monitor for changes in contamination levels, identify process improvements, and maintain sterility assurance of their medical products.
If your medical device has contact with human tissue, it is a safe bet that you will be required to conduct biocompatibility testing. Biocompatibility testing is used to determine the “potential for an unacceptable adverse biological response resulting from contact of the component materials of the device with the body”. The FDA relies heavily on ISO 10993 as the guiding force for biocompatibility testing in medical devices. This ISO standard is rooted in a risk-based approach to testing that the FDA views as the gold standard to ensure that medical devices do not cause adverse local or systemic effects due to contact with human tissue...
Toxicological testing for medical devices focuses on biocompatibility rather than pharmacology. Devices are a diverse category ranging from bandages to pacemakers. Testing assesses the safety of device materials and potential leachables through established biocompatibility standards rather than traditional toxicology studies for drugs. For most Class II and III devices, testing relies on a predicate device through the 510(k) process rather than full premarket approval and clinical trials. The goal is to evaluate biological hazards while ensuring reasonable safety based on prior human exposure to similar materials.
The document summarizes changes to ISO 14155:2020 for clinical investigations involving medical devices. It notes that the standard now explicitly includes post-market investigations and software devices. Key changes include expanded risk-based monitoring allowing on-site or centralized approaches, new event escalation procedures, and emphasis on risk management throughout the clinical trial process. While GCP principles are becoming more aligned between ISO 14155 and ICH-GCP, some differences remain in adverse event reporting and how product risks and training are addressed.
This document discusses the FDA's recent release of draft guidelines for biosimilar drugs. The guidelines were created to establish a regulatory pathway for approving biosimilars in the US, similar to the process that exists for generic small molecule drugs. The guidelines address issues like ensuring biosimilarity to the reference product and assessing potential immunogenicity concerns. While an important first step, additional guidance is still needed for complex nonbiologic drugs that do not fit neatly into the biologic or small molecule categories. Some groups advocate for a cautious approach to ensure patient safety, including requirements for clinical studies and traceability measures for pharmacovigilance.
The safety monitoring in a clinical trail accompanies by common practices in safety monitoring, communicating safety information among stakeholders in a clinical trail.
7.Safety Monitoring in Clinical Trails.pptxbrahmaiahmph
This document discusses safety monitoring in clinical trials. It outlines the key stakeholders in safety monitoring, including sponsors, subjects, investigators, institutional review boards, data and safety monitoring boards, and regulatory authorities. It emphasizes that monitoring patient safety throughout clinical trials is critical. Sponsors must work with all stakeholders to ensure a systematic approach to safety using tools like the clinical trial protocol, informed consent form, case report forms, and periodic safety updates. Timely communication of safety information among stakeholders is important to protect participant safety.
This document discusses medical devices and their classification and regulation. It defines medical devices as instruments or articles intended for medical purposes like diagnosis, treatment or prevention of disease. Medical devices are classified based on risk into Class I, II or III, with Class III posing the highest risk. The document then outlines the key phases in the lifecycle of a medical device from development and manufacturing to packaging, labeling, advertising, sale, use and disposal. It emphasizes that proper design, manufacturing practices and use are important to ensure medical device safety.
medical devices and invitro diagnosis by rahul sagar, m. pharm(dra), bbau luc...Brajesh Kumar
This presentation provides an overview of medical device validation. It discusses the categories of medical devices and regulatory requirements for validation. The presentation covers validation concepts for medical devices including process validation and risk assessment. Analytical and clinical validation methods are described for in vitro diagnostic tests. Finally, the FDA regulatory perspectives on medical devices based on risk classification are summarized.
Pharmacovigilance safety Mon. in clinical trials.pptxRoshan Yadav
Pharmacovigilance involves monitoring drug safety and adverse effects during clinical trials. Safety monitoring is critical and requires collaboration between stakeholders like sponsors, investigators, ethics committees, and regulators. Common safety monitoring practices include sponsors developing protocols detailing reporting procedures, investigators collecting data in case report forms, and ethics committees and data safety monitoring boards regularly reviewing accumulating trial data to protect participants.
Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It plays a crucial role in ensuring the safety and monitoring the risks associated with pharmaceutical products throughout their lifecycle, from pre-market clinical trials to post-marketing surveillance.
Here are some key aspects of pharmacovigilance and drug safety:
Adverse Drug Reaction (ADR) Monitoring: Pharmacovigilance systems aim to identify and monitor adverse drug reactions, which are harmful and unintended responses to medications. Healthcare professionals and patients are encouraged to report suspected ADRs to regulatory authorities or pharmacovigilance programs, enabling the ongoing collection and analysis of safety data.
Signal Detection: Pharmacovigilance activities involve the systematic monitoring and analysis of safety data to identify potential signals or patterns that may indicate new or previously unrecognized risks associated with a drug. This involves the use of various tools and methods, such as data mining, statistical analysis, and signal management, to detect and investigate potential safety concerns.
Benefit-Risk Assessment: Pharmacovigilance plays a critical role in assessing the balance between the benefits and risks of medications. By collecting and analyzing safety data from various sources, including clinical trials and post-marketing surveillance, regulators and healthcare professionals can evaluate the overall benefit-risk profile of drugs and make informed decisions regarding their use.
Regulatory Reporting: Pharmaceutical companies are required to report safety data and suspected adverse reactions to regulatory authorities as part of their regulatory obligations. These reports provide important information for regulatory decision-making, including labeling updates, contraindications, or restrictions on drug use.
Post-Marketing Surveillance: Once a drug is approved and available on the market, pharmacovigilance activities continue to monitor its safety in real-world clinical practice. Post-marketing surveillance systems track and evaluate the safety of drugs in larger and more diverse patient populations, detecting rare or long-term adverse events that may not have been identified during clinical trials.
Risk Management Strategies: Pharmacovigilance also involves the development and implementation of risk management strategies to minimize or mitigate known risks associated with specific drugs. This may include prescribing restrictions, monitoring requirements, educational materials for healthcare professionals and patients, and communication of safety information.
International Collaboration: Pharmacovigilance operates on a global scale, with international collaboration and information sharing being essential for timely detection and response to drug safety issues. Regulatory agencies, healthcare organizations, and pharmacovigilance netw
pharmacovigilance in INDIA,US,EUROPEAN UNIONgarimasaini33
The document discusses pharmacovigilance requirements and methods in India, the US, and the European Union. It outlines key pharmacovigilance methods like passive surveillance using spontaneous reports, stimulated reporting, and active surveillance. It also discusses additional requirements like periodic safety update reports, post-marketing trials, adverse event reporting to regulatory authorities, and considerations for vaccine pharmacovigilance including investigating serious rare adverse reactions and batch-related adverse reactions.
Regulation of biosimilars in India is overseen by the Central Drugs Standard Control Organization (CDSCO). Biosimilars must demonstrate similarity to an approved reference biologic in terms of quality, safety and efficacy through comparative clinical and preclinical studies. The guidelines allow for waiving late-stage clinical trials if early studies show high similarity. Three approval protocols exist based on whether the product is indigenous or imported and if the final product contains genetically modified organisms. Biosimilars offer to increase access to biologic treatments in India at a lower cost than originator biologics.
This document provides a high-level overview of the vaccine development process from research and testing in animals through clinical trials in humans and regulatory approval. It discusses key stages including preclinical research in animal models to test safety and efficacy, phases of human clinical trials, requirements for good manufacturing practices and regulatory compliance, and the role of quality assurance. It also provides examples of DVC's experience developing vaccines for biodefense threats like anthrax, smallpox, and plague.
The document outlines WHO guidelines for good manufacturing practices (GMP) in the pharmaceutical industry. It discusses how GMP ensures quality control throughout the production process, from procurement of materials to finished products. Key aspects covered include facilities and equipment qualification, sanitary conditions, documentation practices, personnel training, and quality control testing. Adhering to GMP is important for minimizing risks and ensuring patient safety.
Upstream Viral Safety: A Holistic Approach to Mitigating Contamination RisksMilliporeSigma
The document discusses strategies for mitigating viral contamination risks in upstream biomanufacturing processes. It outlines a holistic approach involving careful selection and testing of raw materials, risk analysis to identify high-risk components, and various mitigation technologies like gamma irradiation, HTST pasteurization, and virus retentive filtration. Virus retentive filters designed specifically for cell culture media can provide over 4 logs of viral reduction while maintaining media performance. Combined with other controls, these strategies aim to prevent viral contamination upstream and reduce risks of disruption to operations.
Similar to A Complete Guide about Biocompatibility for Medical Devices and Biocompatibility Testing (20)
SATTA MATKA SATTA FAST RESULT KALYAN TOP MATKA RESULT KALYAN SATTA MATKA FAST RESULT MILAN RATAN RAJDHANI MAIN BAZAR MATKA FAST TIPS RESULT MATKA CHART JODI CHART PANEL CHART FREE FIX GAME SATTAMATKA ! MATKA MOBI SATTA 143 spboss.in TOP NO1 RESULT FULL RATE MATKA ONLINE GAME PLAY BY APP SPBOSS
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
[To download this presentation, visit:
https://www.oeconsulting.com.sg/training-presentations]
This presentation is a curated compilation of PowerPoint diagrams and templates designed to illustrate 20 different digital transformation frameworks and models. These frameworks are based on recent industry trends and best practices, ensuring that the content remains relevant and up-to-date.
Key highlights include Microsoft's Digital Transformation Framework, which focuses on driving innovation and efficiency, and McKinsey's Ten Guiding Principles, which provide strategic insights for successful digital transformation. Additionally, Forrester's framework emphasizes enhancing customer experiences and modernizing IT infrastructure, while IDC's MaturityScape helps assess and develop organizational digital maturity. MIT's framework explores cutting-edge strategies for achieving digital success.
These materials are perfect for enhancing your business or classroom presentations, offering visual aids to supplement your insights. Please note that while comprehensive, these slides are intended as supplementary resources and may not be complete for standalone instructional purposes.
Frameworks/Models included:
Microsoft’s Digital Transformation Framework
McKinsey’s Ten Guiding Principles of Digital Transformation
Forrester’s Digital Transformation Framework
IDC’s Digital Transformation MaturityScape
MIT’s Digital Transformation Framework
Gartner’s Digital Transformation Framework
Accenture’s Digital Strategy & Enterprise Frameworks
Deloitte’s Digital Industrial Transformation Framework
Capgemini’s Digital Transformation Framework
PwC’s Digital Transformation Framework
Cisco’s Digital Transformation Framework
Cognizant’s Digital Transformation Framework
DXC Technology’s Digital Transformation Framework
The BCG Strategy Palette
McKinsey’s Digital Transformation Framework
Digital Transformation Compass
Four Levels of Digital Maturity
Design Thinking Framework
Business Model Canvas
Customer Journey Map
How MJ Global Leads the Packaging Industry.pdfMJ Global
MJ Global's success in staying ahead of the curve in the packaging industry is a testament to its dedication to innovation, sustainability, and customer-centricity. By embracing technological advancements, leading in eco-friendly solutions, collaborating with industry leaders, and adapting to evolving consumer preferences, MJ Global continues to set new standards in the packaging sector.
Anny Serafina Love - Letter of Recommendation by Kellen Harkins, MS.AnnySerafinaLove
This letter, written by Kellen Harkins, Course Director at Full Sail University, commends Anny Love's exemplary performance in the Video Sharing Platforms class. It highlights her dedication, willingness to challenge herself, and exceptional skills in production, editing, and marketing across various video platforms like YouTube, TikTok, and Instagram.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
IMPACT Silver is a pure silver zinc producer with over $260 million in revenue since 2008 and a large 100% owned 210km Mexico land package - 2024 catalysts includes new 14% grade zinc Plomosas mine and 20,000m of fully funded exploration drilling.
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
❼❷⓿❺❻❷❽❷❼❽ Dpboss Matka Result Satta Matka Guessing Satta Fix jodi Kalyan Final ank Satta Matka Dpbos Final ank Satta Matta Matka 143 Kalyan Matka Guessing Final Matka Final ank Today Matka 420 Satta Batta Satta 143 Kalyan Chart Main Bazar Chart vip Matka Guessing Dpboss 143 Guessing Kalyan night
Storytelling is an incredibly valuable tool to share data and information. To get the most impact from stories there are a number of key ingredients. These are based on science and human nature. Using these elements in a story you can deliver information impactfully, ensure action and drive change.
The 10 Most Influential Leaders Guiding Corporate Evolution, 2024.pdfthesiliconleaders
In the recent edition, The 10 Most Influential Leaders Guiding Corporate Evolution, 2024, The Silicon Leaders magazine gladly features Dejan Štancer, President of the Global Chamber of Business Leaders (GCBL), along with other leaders.
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
How to Implement a Real Estate CRM SoftwareSalesTown
To implement a CRM for real estate, set clear goals, choose a CRM with key real estate features, and customize it to your needs. Migrate your data, train your team, and use automation to save time. Monitor performance, ensure data security, and use the CRM to enhance marketing. Regularly check its effectiveness to improve your business.
A Complete Guide about Biocompatibility for Medical Devices and Biocompatibility Testing
1. A Complete Guide about Biocompatibility for Medical
Devices and Biocompatibility Testing
Biocompatibility ensures that a device is safe for any person who
undergoes medical testing through that particular machine.
Unintentional damages caused by a device can be life-threatening
and may cause additional damages to the patient. Hence, every
medical device needs to undergo a biocompatibility test to ensure
it is safe.
2.
3. The term biocompatibility is used to denote the interaction
between a medical device and the physiological and tissue
system of a patient that comes in contact with the machine for
treatment or diagnosis. It is an essential part of the overall safety
examination for any machine.
4. Biocompatibility for medical devices depend on different
factors like-
•the chemical and physical nature of the machine and its parts
•Patients and the type of patients that it will treat
•The duration of the period used to use a particular machine
on one patient
5. Manufacturers of medical machines use this biocompatibility
test to ensure that their machines are safe and maintain the
safety regulations before going on the market. ISO 10933-1 and
FDA guidelines have laid the importance of a risk-based
approach for biocompatibility testing. That means a
manufacturer needs to get biocompatibility testing performed
on the machine as a whole and on its different components to
ensure an all-round safety.
6. Biomedical compatibility testing has become flexible in modern
times. The biocompatibility testing for dental materials and
other medical equipment was rigid in the past. That included an
approach to free checkbox testing. The previous method was not
full-proof and often was not feasible to address the risks faced by
the patients. Hence, manufacturers, testing labs, and biomedical
regulatory organizations came with this new procedure that
emphasizes patient safety in a better way.
Steps for biocompatibility testing-
7. In modern times, the biomedical compatibility testing
is done in three steps-
•Biological Evaluation Plan (BEP)
It is the first step. Initially, a Biological Evaluation Plan (BEP) is made to
survey gadget materials, recognize expected dangers, and recommend
potential assessments and testing to address the dangers distinguished
depending on the idea of patient contact of the gadget. This fills in as an
underlying danger appraisal laid out in ISO 10993-1 and gives great inward
documentation of the methodology used to address biocompatibility. This
arrangement can be imparted to the FDA during a free pre-accommodation
conversation.
8. •Testing for risks identified in BEP
In the second step, the gadget is assessed and tried utilizing an
assortment of techniques to address the potential dangers recognized in
the BEP. These dangers (and related tests) incorporate those recorded in
Annex A of ISO 10993-1. Regularly, this is cultivated utilizing a mix of the
accompanying:
●Customary in vivo or in vitro organic tests.
●Science tests are followed by the toxicological danger
evaluation.
●Composed evaluation is dependent on logical writing data and
clinical utilization of the materials.
9. •Biological Evaluation Report or BER
At the third and last step, the consequences of all things
considered and composed assessments ought to be summed up in
a capstone Biological Evaluation Report (BER) that is submitted
alongside test results to the FDA.
10. Hence, if you are trying to buy any medical equipment, make sure
to buy something that has passed the biocompatibility test and is
safe for your patients.
11. CONTACT US
We are looking forward to help you - “please contact us”
Info@biocomptesting.com
949 315 7200
13845 Alton
Pkwy Suite A
Irvine, CA 92618
http://www.biocomptesting.com/